Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile, with Low Incidence of Grade 3 and 4 Neuropathy WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- The study also suggests...
[read full story]